Tech Company Financing Transactions
SignaCor Therapeutics Funding Round
On 3/9/2026, SignaCor Therapeutics announced $330 thousand in funding from Zinc.
Transaction Overview
Company Name
Announced On
3/9/2026
Transaction Type
Venture Equity
Amount
$330,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Healthcare IT
Mailing Address
63 University Road
?Belfast, Northern Ireland, BT7 1NF
UK
?Belfast, Northern Ireland, BT7 1NF
UK
Phone
Undisclosed
Website
Email Address
Overview
SignaCor, a UK based, clinical stage biotech company are pioneering a first-in-class therapeutic approach to symptomatic hypertrophic cardiomyopathy (HCM); One that goes beyond symptom management to target the underlying disease pathology.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
John Fox
Chief Executive Officer
Chris Watson
Chief Operating Officer
Darach Neeson
Browse more venture capital transactions:
Prev: 3/9/2026: Mega venture capital transaction
Next: 3/9/2026: Kast venture capital transaction
Share this article
News on VC Transactions
We do our best to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs